The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
about
Eosinophilia in Hematologic DisordersFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersPathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldSrc activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinasesIndolent T-lymphblastic proliferation: report of a case involving the upper aerodigestive tractThe Fibroblast Growth Factor signaling pathwayDevelopment of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genesAllogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic LeukemiaPonatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromePonatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalitiesFibroblast growth factors and their receptors in cancer.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Chromosomal aberrations and fusion genes in myeloid malignancies.Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusionFunctional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.Pediatric T-cell acute lymphoblastic leukemia.Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation.Reply to the letter by Yang et al. RE: acute myeloid leukemia associated with FGFR1 abnormalities.Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges.Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm.Signaling by cytosolic FGFR1 fusion mutantsPrimary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.Dimerization of cytosolic FGFR1 fusion proteinsTyrosine kinase inhibitors bind and inhibit cytosolic FGFR1 fusion dimer phosphorylationPhosphorylation of STAT5 by cytosolic FGFR1 fusionsHyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion.Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
P2860
Q26799611-91C93134-0942-4CA0-B957-640E5F34D042Q26998955-4D9A8889-359D-4872-ACF2-AEB438A4B081Q27003331-2E76A0AD-22B1-418D-99B9-4E42AD2306FDQ28248761-6312CA44-38F9-40D9-86E6-E15DE0D73A4DQ34371810-7A7BB188-1222-46A4-9B2C-247477557277Q34467171-828D6CAE-A02B-4593-B960-BF97C782AE4DQ34525925-1CD4536F-E74E-4D8F-8E34-AFF853F9EFB7Q35585501-C2712243-D36D-4C8F-BF4A-C9773CFAEF7FQ35786869-3EB9DDD8-B42B-4D9C-BEFB-194DE9F83D9CQ36307383-CCD12927-3235-4304-B516-56E800259A25Q36498390-200719A2-EB35-44BA-97E8-DDACD23C4FE6Q36776253-F2CA6C64-0395-416D-B155-EFCAC09CCCA0Q37895306-BD98BC4A-47DE-4AD6-A20C-EC4C38E2361DQ37919976-B2CB8AA2-3DBC-44B3-AD1B-D791CAAB67E6Q38044772-D5771DE4-4FC1-4BB9-B561-A11ABA6CEDCAQ38718712-DF33E603-BF9A-4BC2-AEFB-958243BFDAD8Q38833773-5F2142F5-EC04-4A9A-B5C6-BE2DD8530A6EQ38956273-7ACB83C8-4AB3-4CA0-B43F-22062C5D95AEQ40974422-AC8A3549-F5A3-40C7-B82B-EC846317C4A1Q42721685-D3951B6B-BC9F-4EE6-BDA6-03FEAB4F76FFQ43130085-32517CA6-07EA-404B-B4E6-BA04BD2F9B16Q43702054-78DA1AD7-5BF0-4F85-9EEC-91458592C1FEQ44094155-544B38C5-8F4E-44AA-AF4B-873AE07EE4FEQ44096802-141A2B87-A047-49CC-8257-8C3E7392D7B0Q44810213-FC6852F2-7DFD-4D60-B5DC-A24D7DCD0BA1Q45314363-B8CB57F8-B864-490A-BC37-202C322C8760Q48109911-2724E7D9-118D-472E-8594-06E60FEFE344Q48227433-66DBCE25-9547-4A84-9D5A-571208E15351Q50288666-DD3DEE76-4981-4F13-AD99-597A709B035FQ50288670-9E5E1CEE-AD4B-416B-A3B8-3A8BB088CFA1Q50288682-78FF3AE8-A3EA-44A1-9DE2-1FF5E44D3C39Q51051812-92B9CEC7-F0A9-4A7C-BF2A-A23FCC02DC38Q53854556-5564A6A9-3003-47EC-B8EC-4A280DE884EDQ54281716-63E007C0-380A-4BEB-A4CF-9CAB3BD9EF3A
P2860
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@ast
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@en
type
label
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@ast
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@en
prefLabel
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@ast
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@en
P2093
P2860
P1433
P1476
The kinase inhibitor TKI258 is ...... /lymphoma and t(7;8)(q22;p11).
@en
P2093
Bartosz Wasag
Els Lierman
Peter Meeus
Peter Vandenberghe
P2860
P304
P356
10.3324/HAEMATOL.2010.036558
P577
2011-02-17T00:00:00Z